This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Global Blood (GBT) Gets FDA Nod for Oxbryta Label Expansion
by Zacks Equity Research
The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.
Forma's (FMTX) Etavopivat Proves Safety Profile in SCD Study
by Zacks Equity Research
Forma's (FMTX) investigational PKR activator, etavopivat significantly improves anemia and red blood cell health in patients with sickle cell disease.
Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.
Global Blood Therapeutics (GBT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -2.73% and -3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review
by Zacks Equity Research
The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.
Why Is Global Blood (GBT) Down 7.5% Since Last Earnings Report?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 4.27% and 8.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Global Blood (GBT) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -18.63% and -8.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Global Blood Therapeutics (GBT) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.